Press Releases
May 6, 2024
Panbela Announces Issuance of New US & Canada Patent for Claims of a Fixed Dose Combination of Eflornithine and Sulindac
May 1, 2024
Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
April 30, 2024
Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week (DDW)
April 22, 2024
Panbela Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
Trial’s lower-than-expected event rate suggests improved survival outcomes
April 18, 2024
Panbela Announces Poster Presentation at American Association for Cancer Research
Ivospemin/doxorubicin combination modulates polyamine metabolism to improve survival in murine ovarian cancer models
View/download poster presentation »
March 26, 2024
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
March 12, 2024
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on 3/26/24
February 15, 2024
Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
February 1, 2024
Panbela Announces Closing of Approximately $9.0 Million Public Offering
Events & Presentations